Skip to main content

Table 1 Patient characteristics

From: Chemotherapy-induced nausea and vomiting (CINV) with carboplatin plus pemetrexed or carboplatin plus paclitaxel in patients with lung cancer: a propensity score-matched analysis

Characteristics

Before propensity score matching

After propensity score matching

CBDCA+PEM

CBDCA+PTX

p-value

CBDCA+PEM

CBDCA+PTX

p-value

(n = 135)

(n = 105)

 

(n = 94)

(n = 94)

 

n

(%)

n

(%)

 

n

(%)

n

(%)

 

Sex

Male

84

(62.2)

89

(84.8)

< 0.001

78

(83.0)

78

(83.0)

1.000

Female

51

(37.8)

16

(15.2)

 

16

(17.0)

16

(17.0)

 

Age, years

< 65

56

(41.5)

46

(43.8)

0.793

37

(39.4)

43

(45.7)

0.461

≥65

79

(58.5)

59

(56.2)

 

57

(60.6)

51

(54.3)

 

Motion sickness

No

122

(90.4)

99

(94.3)

0.338

85

(90.4)

89

(94.7)

0.406

Yes

13

(9.6)

6

(5.7)

 

9

(9.6)

5

(5.3)

 

Drinking habit

No

78

(57.8)

52

(49.5)

0.240

45

(47.9)

45

(47.9)

1.000

Yes

57

(42.2)

53

(50.5)

 

49

(52.1)

49

(52.1)

 

Number of antiemetics

2

95

(70.4)

91

(86.7)

0.003

80

(85.1)

80

(85.1)

1.000

3

40

(29.6)

14

(13.3)

 

14

(14.9)

14

(14.9)

 
  1. CBDCA+PEM carboplatin+pemetrexed, CBDCA+PTX carboplatin+paclitaxel